Top

Published in:

01-03-2015 | Original Paper

Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

Authors: Tianxiang Ge, Qiujin Shen, Ning Wang, Yurong Zhang, Zhouhong Ge, Wei Chu, Xiufang Lv, Fengbo Zhao, Weifeng Zhao, Jia Fan, Wenxin Qin

Published in: Medical Oncology | Issue 3/2015

Abstract

The timely diagnosis and effective treatment are essential for improving the survival and prognosis of hepatocellular carcinoma (HCC) patients. Alpha-fetoprotein (AFP) is the most widely used biomarker for diagnosis of HCC, but the low sensitivity and specificity limits its clinical application. In this study, we evaluated the diagnostic capability of the combination of AFP with two novel potential biomarkers, dickkopf-1 (DKK1) and osteopontin (OPN), for HCC in 390 participants including 89 patients with HCC, 36 patients with liver cirrhosis, 65 patients with chronic hepatitis B, and 200 health controls. We found the combination of all three markers as a panel showed a better diagnostic performance than that of AFP alone, with increased AUC [0.948 (95 % CI 0.921–0.968) vs. 0.831 (95 % CI 0.790–0.867)] and sensitivity (88.76 vs. 71.91 %). Moreover, this combination showed a great improvement in diagnosing early-stage HCC patients. In conclusion, the combined use of AFP, DKK1, and OPN as a biomarker panel could enhance the diagnostic ability for HCC.

Available only for authorised users

Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13. doi:10.1634/theoncologist.2010-S4-05.CrossRefPubMed

Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–9. doi:10.3322/caac.21161.CrossRefPubMed

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38. doi:10.1016/j.jhep.2006.05.013.CrossRefPubMed

Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130(9):497–513. doi:10.1007/s00432-004-0572-9.CrossRefPubMed

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15):1437–47. doi:10.1056/NEJMoa0901282.PubMedCentralCrossRefPubMed

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. doi:10.1093/jnci/djn134.CrossRefPubMed

Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology (Baltimore, MD). 1990;12(6):1420–32.CrossRef

Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology (Baltimore, MD). 2005;42(5):1208–36. doi:10.1002/hep.20933.CrossRef

Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–31. doi:10.1056/NEJM198405313102204.CrossRefPubMed

10.

Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer. 1988;61(4):769–74.CrossRefPubMed

11.

Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23(10):1541–8. doi:10.1111/j.1440-1746.2008.05395.x.CrossRefPubMed

12.

Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8. doi:10.1053/j.gastro.2009.04.005.PubMedCentralCrossRefPubMed

13.

Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, et al. A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013;87(2):121–31. doi:10.1159/000346080.CrossRefPubMed

14.

Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357–62. doi:10.1038/34848.CrossRefPubMed

15.

Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al. Kremen proteins are dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002;417(6889):664–7. doi:10.1038/nature756.CrossRefPubMed

16.

Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50(5):948–57. doi:10.1016/j.jhep.2008.11.020.CrossRefPubMed

17.

Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26. doi:10.1016/S1470-2045(12)70233-4.CrossRefPubMed

18.

Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16(4):885–93.CrossRefPubMed

19.

Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39(4):410–33. doi:10.1053/j.seminoncol.2012.05.001.CrossRefPubMed

20.

Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci Off J Soc Toxicol. 2008;103(1):4–13. doi:10.1093/toxsci/kfm246.CrossRef

21.

Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (Baltimore, MD). 2012;55(2):483–90. doi:10.1002/hep.24703.CrossRef

22.

Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107(1):64–74. doi:10.1038/ajg.2011.312.PubMedCentralCrossRefPubMed

23.

Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. doi:10.1186/2046-4053-2-37.PubMedCentralCrossRefPubMed

24.

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology (Baltimore Md). 2009;50(3):661–2. doi:10.1002/hep.23190.CrossRef

25.

Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore Md). 2011;53(3):1020–2. doi:10.1002/hep.24199.CrossRef

26.

Block T, Mehta AS, London WT. Hepatocellular carcinoma of the liver. Cancer Biomark Sect A Dis Markers. 2010;9(1–6):375–83. doi:10.3233/CBM-2011-0165.

27.

Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57(11):1592–6. doi:10.1136/gut.2008.149062.CrossRefPubMed

28.

Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33(5):437–47. doi:10.1016/j.ctrv.2007.04.001.CrossRefPubMed

29.

Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67(6):2517–25. doi:10.1158/0008-5472.CAN-06-3369.CrossRefPubMed

30.

Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009;55(9):1656–64. doi:10.1373/clinchem.2009.125641.CrossRefPubMed

31.

Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int Off J Int Assoc Study Liver. 2011;31(10):1494–504. doi:10.1111/j.1478-3231.2011.02597.x.CrossRef

32.

Yang H, Chen GD, Fang F, Liu Z, Lau SH, Zhang JF, et al. Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma. Int J Biol Markers. 2013;28(3):286–97. doi:10.5301/jbm.5000015.CrossRef

33.

Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416–23. doi:10.1038/nm843.CrossRefPubMed

34.

Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010;103(6):861–9. doi:10.1038/sj.bjc.6605834.PubMedCentralCrossRefPubMed

35.

Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep. 2011;25(2):433–41. doi:10.3892/or.2010.1106.CrossRefPubMed

36.

Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Nat Compr Cancer Netw JNCCN. 2009;7(4):350–91.

37.

Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206–13.CrossRefPubMed

38.

Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037–44. doi:10.1111/j.1582-4934.2010.01115.x.PubMedCentralCrossRefPubMed

Title: Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma
Authors: Tianxiang Ge
Qiujin Shen
Ning Wang
Yurong Zhang
Zhouhong Ge
Wei Chu
Xiufang Lv
Fengbo Zhao
Weifeng Zhao
Jia Fan
Wenxin Qin
Publication date: 01-03-2015
Publisher: Springer US
Published in: Medical Oncology / Issue 3/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0367-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Continuous, low-dose capecitabine for patients with recurrent colorectal cancer

Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations

p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ

Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer

Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity

Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page